<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13404">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932423</url>
  </required_header>
  <id_info>
    <org_study_id>NU377</org_study_id>
    <nct_id>NCT02932423</nct_id>
  </id_info>
  <brief_title>Metabolic Response to Beverages With Various Sweetening Systems Consumed During Meal in Overweight and Obese Subjects</brief_title>
  <acronym>AQUAGLU-1</acronym>
  <official_title>Impact of Beverage Consumption With Varying Sweetening Systems During Meal on Post-prandial Glucose and Insulin Concentrations, and Lipid Metabolism in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to investigate the effect of drinking a
      sugar-sweetened beverage along with a meal on insulin concentrations and, glucose and lipid
      metabolism, in overweight and obese subjects, during a 10-hour visit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in maximum increment value of insulin concentration during first afternoon phase between each test product and the comparative product</measure>
    <time_frame>6 days (with 17 time points on each day)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>1 - Snack</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - No snack</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control product E</intervention_name>
    <description>Plain water</description>
    <arm_group_label>1 - Snack</arm_group_label>
    <arm_group_label>2 - No snack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test product A</intervention_name>
    <description>Beverage with no sugar but sweetener</description>
    <arm_group_label>1 - Snack</arm_group_label>
    <arm_group_label>2 - No snack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test product B</intervention_name>
    <description>Beverage with 22 g/L sugar and sweetener</description>
    <arm_group_label>1 - Snack</arm_group_label>
    <arm_group_label>2 - No snack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test product C</intervention_name>
    <description>Beverage with 33 g/L sugar and sweetener</description>
    <arm_group_label>1 - Snack</arm_group_label>
    <arm_group_label>2 - No snack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test product D</intervention_name>
    <description>Beverage with 47 g/L sugar and sweetener</description>
    <arm_group_label>1 - Snack</arm_group_label>
    <arm_group_label>2 - No snack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparative product F</intervention_name>
    <description>Beverage with 98 g/L sugar</description>
    <arm_group_label>1 - Snack</arm_group_label>
    <arm_group_label>2 - No snack</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject, upon briefing of the content of the present study, fully understanding and
             agreeing to its objective and having given written (dated and signed) informed
             consent form to take part in the study

          -  Subject who is able to communicate well with the investigator and to comply with the
             requirements of the entire study

          -  If of child bearing potential, female subject must be using or complying with one of
             the following medically approved methods of contraception such as, but not
             exclusively: oral birth control pills (at least 1 full monthly cycle prior to study
             product administration); intra-uterine device (IUD); double barrier methods (such as
             condoms and spermicide)

          -  Subject with a body mass index (BMI) between 25 and 35 kg/m² inclusive

        Exclusion Criteria:

          -  Pregnant woman, based on positive urine pregnancy test, or planning to become
             pregnant during the study or breast-feeding woman

          -  Surgical operation on digestive tract, except appendectomy

          -  Subject who had any surgery or intervention requiring a general anaesthesia in the
             preceding 4 weeks, or who plans to have one during the course of the study

          -  Subject with diagnosed or suspected allergy or hypersensitivity to any food
             ingredient, including components of the study products (ingredients of
             sugar-sweetened beverages)

          -  Blood donation within the last 3 months or planning to give blood during the course
             of the study

          -  Subject involved in any other clinical study within the preceding month or in the
             exclusion period after another clinical study

          -  Subject in a situation, which in the Investigator's opinion could interfere with
             optimal participation in the present study or could constitute a special risk for the
             subject

          -  Evidence of clinically relevant cardiovascular, metabolic, hematologic, hepatic,
             gastrointestinal, renal, pulmonary, endocrine or psychiatric history of disease as
             determined by medical history, physical examination, and vital signs

          -  Clinically significant abnormal results for urine or blood analyses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanne BOTTIN, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danone Research, Palaiseau, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François JEANNE</last_name>
    <phone>+33 (0) 1 69 35 68 72</phone>
    <email>jean-francois.jeanne@danone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gieres</city>
        <state>Auvergne-Rhône-Alpes</state>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves DONAZZOLO, MD, MSc</last_name>
      <phone>+ 33 (0) 4 38 37 27 47</phone>
      <email>YvesDonazzolo@eurofins.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>October 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sugar-sweetened beverage</keyword>
  <keyword>Overweight</keyword>
  <keyword>Obese</keyword>
  <keyword>Sugar</keyword>
  <keyword>Water</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
